Medigene AG Logo

Medigene AG

Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.

MDG1 | F

Overview

Corporate Details

ISIN(s):
DE000A40ESG2
LEI:
391200I33JD2DKZGDX06
Country:
Germany
Address:
Lochhamer Straße 11, 82152 Planegg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medigene AG is a clinical-stage immuno-oncology platform company focused on developing differentiated T-cell receptor (TCR)-engineered T cell (TCR-T) therapies to treat solid tumors. The company's proprietary end-to-end platform is designed to generate optimal affinity 3S (sensitive, specific, safe) TCRs that can be applied across various modalities, including TCR-T cell engagers and TCR-natural killer cell therapies. Its pipeline includes candidates such as MDG1015, a 3rd generation TCR-T therapy. According to company announcements, insolvency proceedings for the company's assets were opened by court order on August 1, 2025.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-04-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2024-10-16 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-09-18 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-08-14 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 183.1 KB
2024-06-28 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-05-06 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 789.0 KB
2024-03-28 00:00
Annual Report
English 9.9 MB
2024-03-04 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2024-02-23 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 2.1 KB
2023-08-17 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2023 bis zum 30.0…
German 171.2 KB
2023-04-26 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 665.8 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.4 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2022-08-03 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 183.3 KB
2022-05-02 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 779.5 KB

Automate Your Workflow. Get a real-time feed of all Medigene AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medigene AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medigene AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.